BioCentury
ARTICLE | Finance

Mollified by mid-caps

January 7, 2008 8:00 AM UTC

Fund managers are looking to 2008 with more optimism than one might expect from people who saw their portfolios struggle against the benchmarks last year. While some of the optimism may be associated with 2008 not being 2007 and its attendant macroeconomic crises, buysiders are seeing investment opportunities, particularly in the $500 million to $2 billion mid-cap space.

Even though more money was invested in the global biotech sector in 2007 than in any year except 2000 - and in the case of Europe it was the best ever fundraising year for biotechs - investors had a particularly disappointing second half...